Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Accenture (ACN) call put ratio 1 call to 1.2 puts into quarter results
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
August 17, 2026 7:00 AM EDTCombined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics
Slates lead product candidate, SLTE-1009, is a clinical stage, potentially best-in-class subcutaneous anti-PACAP/VIP monoclonal antibody for the preventative treatment of migraine
Concurrent oversubscribed private placement financing of $245 million from a leading syndicate of healthcare investors anticipated to fund operations into 2029
Companies to hold conference call on August 17, 2026, at 8:00 a.m. ET
CAMBRIDGE, Mass. and RALEIGH, N.C., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Fulcrum) (Nasdaq:... More
